WFDC2 and laryngotracheoesophageal cleft: We suggested that clinicians could use HE4 as a biomarker related to the diagnosis and prognosis of EC, OC, and LC in clinical work, so as to improve the understanding of disease diagnosis, efficacy, recurrence, outcome, and prognosis of patients.